Prothena Corporation plc (PRTA) Research

Established in 2012 and headquartered in Dublin, Ireland, Prothena Corporation plc functions as a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapeutic solutions for critical, life-threatening conditions, primarily within the United States. The company's pipeline features several key programs: Birtamimab, an investigational humanized antibody, is currently undergoing Phase III clinical trials for the treatment of AL amyloidosis. Prasinezumab, a humanized monoclonal antibody, is progressing through Phase IIb trials for Parkinson's disease. Prothena has also completed Phase I clinical trials for PRX004, indicated for Transthyretin amyloidosis, and is advancing PRX005 through Phase I for Alzheimer's disease. In its earlier-stage development, Prothena is exploring PRX012 for Alzheimer's disease, alongside a dual Aß-Tau vaccine designed for both the treatment and prevention of Alzheimer's disease. Prothena maintains strategic partnerships, including a comprehensive license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. for antibodies targeting alpha-synuclein. The company also collaborates with Bristol-Myers Squibb on antibody development.

Open Prothena Corporation plc (PRTA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.